Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.
Stahl M, et al. Among authors: podoltsev na.
Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.
Blood Adv. 2018.
PMID: 29685952
Free PMC article.